Physician profile
Gerald D Suh
NPI 1154365450
$3,563.21
in general payments reported to CMS, 2019-2025
21 companies · $1,290 in 2025
The $1,290 reported for 2025 was more than what 84% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $330 · 2020: $199 · 2021: $115 · 2022: $212 · 2023: $1,082 · 2024: $336 · 2025: $1,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,975 · Travel and Lodging: $679 · Education: $52.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,975.19 |
| Travel and Lodging | $679.48 |
| Education | $52.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $2,046.24 | 2022-2025 | |
| Optinose US, INC. | $262.76 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $237.72 | 2019-2022 | |
| Glaxosmithkline, LLC. | $203.97 | 2025 | Nucala |
| Stryker Corporation | $122.93 | 2022 | |
| Phathom Pharmaceuticals, INC. | $120.71 | 2025 | Voquezna |
| Harmony Biosciences LLC | $115.59 | 2020-2025 | |
| Intersect Ent, INC. | $62.82 | 2019-2021 | |
| Genzyme Corporation | $55.97 | 2025 | |
| Sanofi-Aventis U.S. LLC | $52.99 | 2025 | |
| Alk-Abello, INC | $39.57 | 2019-2021 | |
| Integra Lifesciences Corporation | $38.72 | 2025 | Trudi Probe, Relieva Spinplus Nav, Inspira Air |
| Axsome Therapeutics, INC. | $38.44 | 2023-2025 | Sunosi |
| Acclarent, INC | $37.42 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $37.17 | 2025 | Dupixent |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $20.51 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $16.51 | 2025 | Neffy |
| Lilly USA, LLC | $14.86 | 2025 | Zepbound |
| Paratek Pharmaceuticals, INC. | $14.39 | 2025 | Xhance |
| Resmed Corp | $12.87 | 2020 | |
| Novartis Pharmaceuticals Corporation | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Suh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.